Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Honghua dripping pill is a Traditional Chinese Medicine (TCM) botanical product developed by Shanxi Deyuantang Pharmaceutical for the treatment of stable exertional angina pectoris. The formulation is derived from the flower of *Carthamus tinctorius* (Safflower), which is traditionally recognized for its ability to promote blood circulation and resolve blood stasis. In clinical applications for coronary artery disease, it is used to address the TCM pattern of heart blood stasis and obstruction. The drug has undergone Phase II clinical evaluation in China to assess its safety, efficacy, and optimal dosing for improving symptoms of myocardial ischemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Honghua dripping pill.